Clinical data | |
---|---|
Other names | FPF-1070 |
Identifiers | |
CAS Number | |
DrugBank | |
UNII |
Cerebrolysin (developmental code name FPF-1070) is a mixture of enzymatically treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).
Cerebrolysin has also been studied for potential use with a wide variety of neurodegenerative disorders, though research is preliminary.[1] No benefit in the treatment of acute stroke has been found and an increased rate of spontaneous adverse events requiring hospitalization is reported.[2] Some positive effects have been reported when cerebrolysin is used to treat vascular dementia.[3]
Reviews emphasize the need for further high quality studies.[2] In addition, use might be associated with a higher rate of spontaneous adverse events requiring hospitalization.[2] Studies of ischemic stroke in Asian subpopulations found an absence of benefit.[4]
A 2020 study suggested a lack of benefit in hemorrhagic stroke related to cerebral aneurysm.[5]
Reviews of preliminary research indicate a possible improvement in cognitive function using cerebrolysin for vascular dementia and Alzheimer's disease, although further high-quality research is needed.[3][6]
Early studies have suggested potential use of cerebrolysin with a wide variety of neurodegenerative disorders, including traumatic brain injury,[7][8] schizophrenia,[9] multiple sclerosis,[10] cerebral palsy[11] and spinal cord injury[12][13] though research is still preliminary.
In trials studying the use of cerebrolysin after acute stroke, there was no increased risk of "serious adverse events" requiring hospitalization. These were specifically defined as:
In vitro and animal studies suggest neurotrophic effects of cerebrolysin similar to endogenous neurotrophic factors, though its specific molecular pharmacodynamics are not clear.[15] Studies of dementia suggest decreased beta-amyloid deposition.[16]
Cerebrolysin is not a scheduled drug in the United States.[17][18]